Analyst Price Target is $42.44
▲ +25.54% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Invitae in the last 3 months. The average price target is $42.44, with a high forecast of $58.00 and a low forecast of $33.00. The average price target represents a 25.54% upside from the last price of $33.81.
Current Consensus is
The current consensus among 10 investment analysts is to buy stock in Invitae. This Buy consensus rating has held steady for over two years.
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.